Page
%P
45 Result(s)
within
Ronald F. van Vollenhoven
-
Article
Open AccessCorrection: Targeting DORIS Remission and LLDAS in SLE: A Review
-
Article
Open AccessTargeting DORIS Remission and LLDAS in SLE: A Review
Remission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted Definition Of Remission In SLE (DORIS) criteria. Attainment of ...
-
Chapter
Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects all ethnic groups and has a wide age range of onset. The average ages at diagnosis for women and men are approximately 50 and 60 year...
-
Article
Open AccessBaricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial
Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a p...
-
Article
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
The treat-to-target (T2T) concept has improved outcomes for patients with diabetes, hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well-defined, relevant target, taking th...
-
Article
Open AccessUsing adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
A substantial proportion of rheumatoid arthritis (RA) patients discontinues treatment with tumour necrosis factor inhibitors (TNFi) due to inefficacy or intolerance. After the failure of treatment with a TNFi,...
-
Article
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients
Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many patients do not respond adequately. In order to identify genetic predictors of response, we have combined data...
-
Article
Open AccessLong-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
The safety and efficacy of certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) monotherapy (FAST4WARD/NCT00548834) and in combination with methotrexate (MTX) (014/NCT00544154) in active rheumatoid arthritis (R...
-
Article
Open AccessSwitching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this study was to explore the safety and efficacy of open-label tofacitinib following blinded treatment ...
-
Article
Open AccessErratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
-
Article
Open AccessEffectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg × 2, but some data have suggested similar clinical efficacy with 500 mg × 2. The purpose of this study was to compare the effectiveness o...
-
Book
-
Chapter
Conclusions and future outlook
Forty years ago this year George Kohler and Cesar Milstein published an article in Nature describing a method for “continuous cultures of fused cells secreting antibody of predefined specificity” Figure 10.1 [1].
-
Chapter
T-cell Directed Therapy
The role of the T lymphocyte in the pathophysiology of rheumatoid arthritis (RA) remains somewhat unclear. On the one hand, T cells are abundantly present in the inflamed synovium, and in some animal models T ...
-
Chapter
Disease overview
Rheumatoid arthritis (RA) is a chronic inflammatory disease of presumed autoimmune etiology that is characterized by symmetric inflammation of the synovial joints, which may lead to damage to the cartilage and...
-
Chapter
Overview of Biologic Therapies
The discovery of the technology for producing monoclonal antibodies by Kohler and Milstein in (Nature 256:495–497, 1975) heralded a new era in therapeutics: it became possible to design a molecule with a very ...
-
Chapter
B-cell Directed Therapy
Appreciation of the role of B-lymphocytes in the pathogenesis of rheumatoid arthritis (RA) has gone through various cycles. The discovery of rheumatoid factors as a specific marker for the disease pointed to a...
-
Chapter
Novel biologics and small molecules with biologic-like effects
Dozens of cytokines are involved in the inflammatory process and it stands to reason that many of them could be targeted successfully in the treatment of inflammatory diseases.
-
Chapter
General Treatment Aspects
Rheumatoid arthritis (RA) is almost invariably associated with significant symptomatology. In the early stages of the disease, joint pain and stiffness are the dominant symptoms, but patients also frequently e...
-
Chapter
Cytokine inhibitors
Tumor necrosis factor (TNF; formerly designated TNF-α) is a cytokine of central importance in multiple inflammatory processes. Its initial discovery was in the field of oncological research, where in the early...
